摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

H-Phe-氯甲基酮盐酸盐 | 52735-71-4

中文名称
H-Phe-氯甲基酮盐酸盐
中文别名
H-PHE-氯甲基酮盐酸盐
英文名称
L-phenylalanine chloromethyl ketone
英文别名
L-Phe chloromethyl ketone;Phenylalanylmethylchloride;(3S)-3-amino-1-chloro-4-phenylbutan-2-one
H-Phe-氯甲基酮盐酸盐化学式
CAS
52735-71-4
化学式
C10H12ClNO
mdl
——
分子量
197.664
InChiKey
CNNSBPMDYXZFTQ-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    302.0±32.0 °C(Predicted)
  • 密度:
    1.177±0.06 g/cm3(Predicted)
  • 稳定性/保质期:

    如果按照规格正确使用和储存,则不会发生分解,目前没有已知的危险反应。

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    43.1
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 储存条件:
    请将贮藏器密封,并存放在阴凉、干燥处。确保工作环境有良好的通风或排气设施。

SDS

SDS:34acdf08dc20d84a6628e9008e04c645
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: H-Phe-chloromethylketone HCl
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: H-Phe-chloromethylketone HCl
CAS number: 52735-71-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H12ClNO.ClH
Molecular weight: 234.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    H-Phe-氯甲基酮盐酸盐N-甲基吗啉 、 lithium tri-t-butoxyaluminum hydride 、 sodium iodide 、 氯甲酸异丁酯 作用下, 以 四氢呋喃乙醚乙腈 为溶剂, 反应 4.5h, 生成 阿扎那韦
    参考文献:
    名称:
    通过高度非对映选择性还原方法高效,实用地合成HIV蛋白酶抑制剂Atazanavir
    摘要:
    通过采用非对映选择性还原酮亚甲基氮杂-二肽等排物10作为关键和最终步骤,开发了一种有效且实用的HIV-1蛋白酶抑制剂Atazanavir合成方法。通过Felkin -Anh控制,由于笨重和手性的N -(-)的结果,通过三叔丁氧基氢化铝锂在乙醚中还原氨基酮的高非对映选择性,从而得到所需的顺式1,2-氨基醇结构。甲氧基羰基) -升-叔-leucinyl部分为氮保护基团。两个关键中间体的联接器,ñ - (甲氧羰基) -升-叔亮氨酸酰化的苄基肼7和氯甲基酮9通过S N 2反应在我们优化的条件下以高收率提供了氨基酮10。我们的新方法提供了引入末的小号羟基基团和苄基肼和氯甲基酮与早期酰化Ñ - (甲氧羰基) -升-叔-亮氨酸,分别,其赋予高效率和容易纯化。
    DOI:
    10.1021/op7001563
  • 作为产物:
    参考文献:
    名称:
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • 一种医药中间体氯酮的合成方法
    申请人:徐州诺克非医药科技有限公司
    公开号:CN108558703A
    公开(公告)日:2018-09-21
    本发明公开了一种医药中间体氯酮的合成方法,N‑BOC‑L‑苯丙酸、三乙胺氯甲酸乙酯重氮甲烷、Bi(NO3)3·5H2O、NaVO3、聚乙烯吡咯烷酮和对苯二甲酸为主要原料,其所用原料按以下配比:N‑BOC‑L‑苯丙酸、氯甲酸乙酯质量比为5:4;Bi( )3·5H2O、NaVO3质量为3:1;乙烯吡咯烷酮、对苯二甲酸质量比为4:5;本发明的合成工艺采用一锅法在重氮化之后直接通入氯化氢气体制备氯酮,降低了重氮酮取出时重氮甲烷泄漏的风险,同时也降低了工业化操作难度,加入Bi‑V‑O催化剂提高其反应的选择性使得实际的工业产品收率大幅提高。
  • Strategy in Inhibition of Cathepsin B, A Target in Tumor Invasion and Metastasis
    作者:In Taek Lim、Samy O. Meroueh、Mijoon Lee、Mary Jane Heeg、Shahriar Mobashery
    DOI:10.1021/ja0489240
    日期:2004.8.1
    which were screened for cathepsin B inhibitory properties. Compound 2, 1-(2(R)-[1(S)-acetoxy-2-[2(S)-(2,4-difluoro-benzoylamino)-3-phenyl-propionylaminooxy]-2-oxo-ethyl]-pentanoyl)-pyrrolidine-2(S)-carboxylic acid benzyl ester, is the prototype of this novel class of cysteine protease inhibitor that emerged from the search. The molecule modifies the active site of cathepsin B covalently, irreversibly
    组织蛋白酶 B 是一种半胱蛋白酶,是抗癌的重要靶点。这种酶与增强肿瘤侵袭和转移有关,因此组织蛋白酶 B 的抑制剂作为潜在的抗癌和抗转移剂备受追捧。在获得抑制组织蛋白酶 B 的模板方面进行了基于结构的设计工作。基于该模板合成了重点化合物库,筛选了组织蛋白酶 B 抑制特性。化合物2,1-(2(R)-[1(S)-乙酰氧基-2-[2(S)-(2,4-二-苯甲酰基)-3-苯基-丙酰基氧基]-2-氧代-乙基] -戊酰基)-吡咯烷-2(S)-羧酸苄酯,是从搜索中出现的这类新型半胱酸蛋白酶抑制剂的原型。该分子共价、不可逆且有效地修饰组织蛋白酶 B 的活性位点,评估动力学参数的过程。还合成了一组三个明智改变的化合物 2 变体,以探索该抑制剂所提出的作用机制的细节。化合物 2 及其类似物可能被证明是逆转组织蛋白酶 B 在抗癌中的有害作用的有用工具。
  • [EN] REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS<br/>[FR] RÉDUCTION D'ALDÉHYDES ET DE CÉTONES EN ALCOOLS
    申请人:AMERICAN PACIFIC CORP
    公开号:WO2011060302A1
    公开(公告)日:2011-05-19
    The embodiments described herein provide a reduction of an aldehyde or a ketone, such as a Meerwein-Ponnorf-Verley (MPV) reaction of an aldehyde or ketone. In some embodiments, the reaction occurs in the presence of A1[OC(CH3)3]. In some embodiments, the reaction occurs in the presence of an aprotic solvent. In some embodiments, the aldehyde or ketone is an amino aldehyde or an amino ketone wherein the amine is group is protected such that the nitrogen of the amine has no proton. Other embodiments related to compositions and compounds related to the reduction reaction, or to the preparation or use of the aldehyde, the ketone, or the resulting alcohol.
    本文所述实施例提供了醛或酮的还原,例如醛或酮的Meerwein-Ponnorf-Verley(MPV)反应。在某些实施例中,反应发生在A1 [OC(CH3)3]的存在下。在某些实施例中,反应发生在无极溶剂的存在下。在某些实施例中,醛或酮是基醛或基酮,其中基团被保护,使得基的氮没有质子。其他实施例涉及与还原反应相关的组合物和化合物,或与醛、酮或所得醇的制备或使用相关的实施例。
  • KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
    申请人:Bong Yong Koy
    公开号:US20120190086A1
    公开(公告)日:2012-07-26
    The present disclosure relates to engineered ketoreductase polypeptides and uses thereof for the preparation of α chloroalcohols from α chloroketones. Also provided are polynucleotides encoding the engineered ketoreductase polypeptides and host cells capable of expressing the engineered ketoreductase polypeptides.
    本公开涉及工程化的酮还原酶多肽及其在制备α-代醇中的应用。还提供了编码工程酮还原酶多肽的多核苷酸和能够表达工程酮还原酶多肽的宿主细胞。
  • REDUCTION OF ALDEHYDES AND KETONES TO ALCOHOLS
    申请人:Liotta Charles L.
    公开号:US20130096317A1
    公开(公告)日:2013-04-18
    The embodiments described herein provide a reduction of an aldehyde or a ketone, such as a Meerwein-Ponnorf-Verley (MPV) reaction of an aldehyde or ketone. In some embodiments, the reaction occurs in the presence of Al[OC(CH 3 ) 3 ]. In some embodiments, the reaction occurs in the presence of an aprotic solvent. In some embodiments, the aldehyde or ketone is an amino aldehyde or an amino ketone wherein the amine is group is protected such that the nitrogen of the amine has no proton. Other embodiments related to compositions and compounds related to the reduction reaction, or to the preparation or use of the aldehyde, the ketone, or the resulting alcohol.
    本文所述的实施例提供了对醛或酮的还原,例如醛或酮的Meerwein-Ponnorf-Verley(MPV)反应。在某些实施例中,反应发生在Al [OC (CH3) 3]的存在下。在某些实施例中,反应发生在无极溶剂的存在下。在某些实施例中,醛或酮是基醛或基酮,其中基保护基团保护,使得基的氮没有质子。其他实施例涉及与还原反应相关的组合物和化合物,或与醛、酮或所得的醇的制备或使用相关的实施例。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫